Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cosmos Health Inc. - Common Stock (NQ:COSM)

0.2626 +0.0101 (+4.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,345,959
Open 0.2690
Bid (Size) 0.2630 (2,000)
Ask (Size) 0.2700 (500)
Prev. Close 0.2525
Today's Range 0.2518 - 0.2937
52wk Range 0.2464 - 1.320
Shares Outstanding 34,919,920
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants
Via ACCESS Newswire

Performance

YTD
-49.0%
-49.0%
1 Month
-27.6%
-27.6%
3 Month
-30.3%
-30.3%
6 Month
-61.9%
-61.9%
1 Year
-43.5%
-43.5%

More News

Read More
News headline image
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway
Via ACCESS Newswire
News headline image
Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt Program
Via ACCESS Newswire
News headline image
Cosmos Health Announces Withdrawal of Registration Statement on Form S-1
Via ACCESS Newswire
News headline image
Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months
Via ACCESS Newswire
News headline image
Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed
Via ACCESS Newswire
News headline image
Cosmos Health Introduces Fort18 in the United States - A Men's Sexual Stamina Supplement Expanding the 18 Series into Men's Wellness
Via ACCESS Newswire
News headline image
Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months
Via ACCESS Newswire
Top movers in Friday's after hours session ↗
Via Chartmill
News headline image
Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products
Via ACCESS Newswire
News headline image
Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Commercial Traction Observed Across Product Portfolio
Via ACCESS Newswire
News headline image
Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint Health
Via ACCESS Newswire
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
Via Chartmill
News headline image
Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30%
Via ACCESS Newswire
News headline image
Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Growth Continues Into
Via ACCESS Newswire
News headline image
Cosmos Health Receives Third Consecutive Purchase Order from Pharmalink for 60,000 Units of Sky Premium Life Products in the UAE; Cumulative Orders Reach 270,000 Units, Advancing 5-Year Goal of Over 3 million Units
Via ACCESS Newswire
News headline image
Cosmos Health Reports No Impact from Iran and Middle East Conflict; Revenue Continues at All-Time High Levels; NOOR U.S. Expansion on Track to Exceed $12 Million Within 12 Months
Via ACCESS Newswire
News headline image
Cosmos Health Announces Successful EN 12791 Study Results for C-Scrub Wash 4%, Strengthening Expansion into Hospital and Surgical Markets
Via ACCESS Newswire
News headline image
Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Purchases $600,000 of Bitcoin, Expands Digital Asset Holdings to $3,100,000
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Enters into LOI to Acquire $11,500,000 Pharmacy Distribution Network; Remains on Track to Deliver 2027 Revenue Guidance of $155,800,000
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Appoints Globally Recognized AI-Driven Drug Discovery and Clinical-Stage Biotech Expert Dr. Dimitrios Iliopoulos to Advisory Board
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value
From Cosmos Health Inc.
Via GlobeNewswire
News headline image
Cosmos Health Continues UK Retail Expansion for C-Scrub; Now Available at Superdrug, the UK’s Second-Largest Beauty and Health Retailer
From Cosmos Health Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Cosmos Health Inc. - Common Stock publicly traded?
Yes, Cosmos Health Inc. - Common Stock is publicly traded.
What exchange does Cosmos Health Inc. - Common Stock trade on?
Cosmos Health Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cosmos Health Inc. - Common Stock?
The ticker symbol for Cosmos Health Inc. - Common Stock is COSM on the Nasdaq Stock Market
What is the current price of Cosmos Health Inc. - Common Stock?
The current price of Cosmos Health Inc. - Common Stock is 0.2626
When was Cosmos Health Inc. - Common Stock last traded?
The last trade of Cosmos Health Inc. - Common Stock was at 05/26/26 04:00 PM ET
What is the market capitalization of Cosmos Health Inc. - Common Stock?
The market capitalization of Cosmos Health Inc. - Common Stock is 9.17M
How many shares of Cosmos Health Inc. - Common Stock are outstanding?
Cosmos Health Inc. - Common Stock has 9M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.